Live Breaking News & Updates on Emerging Markets Underpin Sustainable

Stay updated with breaking news from Emerging markets underpin sustainable. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Redirecting to Takeda's Growth and Emerging Markets Business Unit Aims to Deliver Double-Digit Revenue Growth Over Next Decade1

Redirecting to Takeda's Growth and Emerging Markets Business Unit Aims to Deliver Double-Digit Revenue Growth Over Next Decade1
q8dailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from q8dailynews.com Daily Mail and Mail on Sunday newspapers.

United Arab Emirates , United States , Buenos Aires , Distrito Federal , Ricardo Marek , Asia Pacific , Exchange Commission , Takeda Pharmaceutical Company Limited , Takeda Pharmaceutical Company , Digit Revenue Growth Expected , Focused Geographic Presence , Patient Access , Addressing Unmet Patient Needs , Emerging Markets Underpin Sustainable , Pharmaceutical Company Limited , Emerging Markets Business Unit , Emerging Markets , Costa Saroukos , Rare Genetic , Plasma Derived Therapies , Emerging Markets Business , South America , Middle East , Annual Report , Technical Success , ஒன்றுபட்டது அரபு அமீரகங்கள் ,

Takeda's Growth and Emerging Markets Business Unit Aims to Deliver Double-Digit Revenue Growth Over Next Decade1

Takeda Pharmaceutical Company Limited
Takeda’s Growth and Emerging Markets Business Unit Aims to Deliver Double-Digit Revenue Growth Over Next Decade1
Friday, March 12, 2021 11:40AM IST (6:10AM GMT)

Aiming for Revenues of JPY 1 Trillion (approximately US$9 Billion2) by FY2030
Double-Digit Revenue Growth Expected to be Driven by a Balanced and Focused Geographic Presence, Portfolio of 14 Global Brands and Wave 1 Pipeline Assets
Commitment to Patient Access to Medicines and Addressing Unmet Patient Needs in Emerging Markets Underpin Sustainable Growth

(TSE:4502/NYSE:TAK) (“Takeda”) today outlined its ambition for above-market, double-digit revenue growth of its Growth and Emerging Markets Business Unit (“GEM BU”). The revenue goal of JPY 1 trillion (approximately US$9 billion) by FY2030 represents more than doubling of current revenues in GEM BU. This potential growth will be primarily driven by a balanced geographical focus and targ ....

United Arab Emirates , United States , Buenos Aires , Distrito Federal , Holly Campbell , Kazumi Kobayashi , Ricardo Marek , Asia Pacific , Exchange Commission , Takeda Pharmaceutical Company Limited , Takeda Pharmaceutical Company , Digit Revenue Growth Expected , Focused Geographic Presence , Patient Access , Addressing Unmet Patient Needs , Emerging Markets Underpin Sustainable , Pharmaceutical Company Limited , Emerging Markets Business Unit , Emerging Markets , Costa Saroukos , Rare Genetic , Plasma Derived Therapies , Emerging Markets Business , South America , Middle East , Annual Report ,